<DOC>
	<DOCNO>NCT02419469</DOCNO>
	<brief_summary>The goal clinical research study learn chemotherapy combination call augment Berlin-Frankfurt-Munster ( BFM ) , also combine ofatumumab rituximab , help control precursor-B ALL LL patient 12-30 year age . The safety drug combination also study . Augmented BFM make daunorubicin , vincristine , prednisone , dexamethasone , PEG asparaginase , methotrexate .</brief_summary>
	<brief_title>Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab Young Adults With Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , Day 1 spinal tap procedure , give cytarabine injection spinal fluid . You receive study drug Induction , Consolidation , Maintenance Courses . Induction Therapy design remove sign leukemia see allow normal blood cell restore . This call remission . Consolidation Maintenance Therapies design cause disease stay remission . The study drug give follow way : - Daunorubicin vein 30 minute - Vincristine vein 15-30 minute - PEG asparaginase vein 15-60 minute - Methotrexate either mouth injection spinal fluid ( intrathecal ) , depend course . When give spinal fluid , cerebrospinal fluid ( CSF ) collect spinal tap test fluid leukemia . If disease spinal fluid start treatment , give additional methotrexate dos week disease present . - Ofatumumab injection vein . If give vein , length infusion depend well tolerate drug . If ofatumumab available , give rituximab vein several ( 4-6 ) hour . - Cyclophosphamide vein 1 hour - Cytarabine injection skin vein . If give vein , length infusion depend well tolerate drug . - Doxorubicin vein . If give vein , length infusion depend well tolerate drug . - Prednisone , 6-Mercaptopurine , dexamethasone , 6-Thioguanine take mouth Within 3 day receive cytarabine , begin Induction Course , last 4 week . In Induction Course , receive : - Daunorubicin vincristine Days 1 , 8 , 15 , 22 - PEG asparaginase 1 time Week 1 - Prednisone day Days 1-28 . - Intrathecal methotrexate Weeks 2 5 spinal tap . If disease spinal fluid start treatment , give additional methotrexate dos week disease present . - Ofatumumab rituximab Days 2 15 Depending respond Induction , may begin Consolidation Courses 1-4 week Induction . You receive Consolidation Course 1 . This course last 8 week , receive : - Cyclophosphamide Weeks 1 5 - Cytarabine around Days 1-4 Days 8-11 4-week cycle - 6-Mercaptopurine Days 1-14 4-week cycle - Vincristine Weeks 3 4 4-week cycle - PEG Asparaginase Weeks 3 7 - Intrathecal methotrexate weekly Month 1 - Ofatumumab rituximab Weeks 1 5 You receive 2 course Consolidation Course 2 . Each course last 7 week , receive : - Vincristine methotrexate every 10 ( +/- 2 ) day 5 dos - PEG Asparaginase Weeks 1 4 - Intrathecal methotrexate Weeks 1 5 - Ofatumumab rituximab Weeks 1 5 You receive Consolidation 3 ( Part A ) . This course last 4 week , receive : - Vincristine doxorubicin Weeks 1 , 2 , 3 - Dexamethasone Days 1-7 Days 15-21 - PEG asparaginase Week 1 - Intrathecal methotrexate Week 1 - Ofatumumab rituximab Weeks 1 3 You receive Consolidation 3 ( Part B ) . This course last 4 week , receive : - Cyclophosphamide Week 1 - Cytarabine 4 day row Weeks 1-2 - 6-Thioguanine every day first 2 week . - Intrathecal methotrexate Weeks 1 2 - Vincristin Weeks 3 4 - PEG Asparaginase Week 3 Once finish Consolidation , receive 24 month Maintenance Therapy . - Vincristine every month . - Dexamethasone 5 day every month . - 6-Mercaptopurine 1 time day - Methotrexate mouth every week . - If ALL , also receive intrathecal methotrexate every 3 month first 12 month maintenance . Study Tests/Procedures : Induction : - Blood ( 3 teaspoon ) draw 2 time week Induction Period routine test . - You bone marrow aspirate biopsy Days 15 29 need check status disease . - About 7 day receive first dose PEG asparaginase , blood ( 1 tablespoon ) drawn check activity drug blood . If drug seem work well , dose may change . - If LL bone marrow find involved disease screening , chest x-ray , CT scan , PET scan measure disease . These scan do 28 day therapy . Consolidation 1 : - Blood ( 3 teaspoon ) draw routine test 2 time week . - You spinal tap intrathecal methotrexate dose . The spinal fluid check leukemia cell . - You bone marrow aspiration end Month 2 check status disease . Consolidation 2 : - Blood ( 3 teaspoon ) draw every 2 week routine test . - You spinal tap intrathecal methotrexate dos . The spinal fluid check leukemia cell . Consolidation 3 ( Part A B ) : - Blood ( 3 teaspoon ) draw least weekly routine test . - You spinal tap intrathecal methotrexate dose . The spinal fluid check leukemia cell . Maintenance : - You spinal tap intrathecal methotrexate dose . The spinal fluid check leukemia cell . - You bone marrow aspiration least every 3-6 month check status disease . Length Study : You may remain study long study doctor think best interest . If disease appear improve Induction , take study . You may take study disease get bad come back treatment , intolerable side effect occur , doctor think best interest , follow study instruction . Follow-up Visits : Your study doctor inform follow-up visit schedule clinic . At follow-up visit physical exam blood ( 1 tablespoon ) drawn routine test . You followed-up next 3 year last dose chemotherapy . This investigational study . The chemotherapy drug use study FDA approve commercially available treatment various type leukemia . The use ofatumumab/rituximab drug combination , well drug combination 's use pediatric patient , investigational . Up 100 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients must precursorB lymphoblastic leukemia lymphoma . 2 . Patients must untreated one prior chemotherapy regimen ALL LL . Previously treat patient analyze separately . 3 . Age 12 30 year old 4 . Patients CNS disease testicular disease eligible . 5 . Intrathecal therapy cytarabine allow prior registration patient convenience . This usually do time diagnostic bone marrow venous line placement avoid second lumbar puncture . Systemic chemotherapy must begin within 72 hour first intrathecal treatment . 6 . Signed informed consent prior start systemic therapy . In event enrollment minor patient , attempt obtain assent patient must document , parental consent must sign . 7 . Echocardiogram do within 7 day start therapy cardiac risk factor ( e.g. , history hypertension myocardial infarction ) 8 . Creatinine &lt; 3 mg/dL bilirubin &lt; 3 mg/dl unless due disease 9 . Zubrod Performance status &lt; 3 10 . Patients receive steroid 72 hour prior study enrollment eligible analyze separately . 11 . Lymphoblasts may positive expression CD20 ofatumumab administration . 1 . Age less twelve year age great 30 year . 2 . More one prior treatment regimen ALL LL . 3 . The patient pregnant unwilling practice appropriate birth control . 4 . Presence Philadelphia chromosome ( 9 ; 22 ) 5 . Laboratory clinical evidence active infectious hepatitis .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Precursor-B acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Lymphoblastic lymphoma</keyword>
	<keyword>LL</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
	<keyword>Daunorubicin</keyword>
	<keyword>Daunorubicin Hydrochloride</keyword>
	<keyword>Cerubidine</keyword>
	<keyword>Daunomycin</keyword>
	<keyword>DNR</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Prednisone</keyword>
	<keyword>PEG asparginase</keyword>
	<keyword>Pegaspargase</keyword>
	<keyword>Oncaspar</keyword>
	<keyword>Polyethylene glycol conjugate lasparaginase-H</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>Arzerra</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Mercaptopurine</keyword>
	<keyword>6-mercaptopurine</keyword>
	<keyword>Purinethol</keyword>
	<keyword>6-MP</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Doxorubicin hydrochloride</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Thioguanine</keyword>
	<keyword>6-thioguanine</keyword>
</DOC>